| First Author | Zhao H | Year | 2018 |
| Journal | Cell Rep | Volume | 25 |
| Issue | 5 | Pages | 1241-1254.e5 |
| PubMed ID | 30380415 | Mgi Jnum | J:270635 |
| Mgi Id | MGI:6278585 | Doi | 10.1016/j.celrep.2018.10.015 |
| Citation | Zhao H, et al. (2018) Apj(+) Vessels Drive Tumor Growth and Represent a Tractable Therapeutic Target. Cell Rep 25(5):1241-1254.e5 |
| abstractText | Identification of cellular surface markers that distinguish tumorous from normal vasculature is important for the development of tumor vessel-targeted therapy. Here, we show that Apj, a G protein-coupled receptor, is highly enriched in tumor endothelial cells but absent from most endothelial cells of adult tissues in homeostasis. By genetic targeting using Apj-CreER and Apj-DTRGFP-Luciferase, we demonstrated that hypoxia-VEGF signaling drives expansion of Apj(+) tumor vessels and that targeting of these vessels, genetically and pharmacologically, remarkably inhibits tumor angiogenesis and restricts tumor growth. These in vivo findings implicate Apj(+) vessels as a key driver of pathological angiogenesis and identify Apj(+) endothelial cells as an important therapeutic target for the anti-angiogenic treatment of tumors. |
